Literature DB >> 17903629

Severe left ventricular dyssynchrony is associated with poor prognosis in patients with moderate systolic heart failure undergoing coronary artery bypass grafting.

Martin Penicka1, Jozef Bartunek, Otto Lang, Karel Medilek, Petr Tousek, Marc Vanderheyden, Bernard De Bruyne, Michaela Maruskova, Petr Widimsky.   

Abstract

OBJECTIVES: The objective of the present study was to assess the relationship between the presence of left ventricular (LV) dyssynchrony and clinical outcome in patients with moderate systolic heart failure undergoing coronary artery bypass graft (CABG) surgery.
BACKGROUND: The presence of LV dyssynchrony is associated with poor prognosis in patients with LV dysfunction.
METHODS: The study consisted of 215 consecutive patients with ischemic cardiomyopathy and dyspnea (age 65 +/- 9 years, 81% male) undergoing CABG. Dyssynchrony was calculated by tissue Doppler imaging from regional time intervals in basal LV segments before and 1 month after CABG. Myocardial viability was assessed using single-photon emission computed tomography (SPECT) before CABG.
RESULTS: Twenty-five patients (11.6%) died within 30 days (in-hospital mortality) of CABG. The presence of pre-CABG dyssynchrony > or =119 ms had the highest predictive accuracy for in-hospital mortality, with a sensitivity of 84% and a specificity of 71%. During the median follow-up period of 359 days (interquartile range 219 to 561), an additional 19 patients (10.3%) died and 34 patients (18.5%) were hospitalized for worsening heart failure. At Cox regression analysis, post-CABG dyssynchrony > or =72 ms and > or =5 viable segments were identified as independent predictors of clinical events, with a hazard ratio (HR) of 5.02, 95% confidence interval (CI) 2.57 to 10.02 (p < 0.001), and an HR of 0.63, 95% CI 0.55 to 0.75 (p < 0.001), respectively. Patients without post-CABG dyssynchrony and with viable myocardium had excellent prognosis compared with patients with severe post-CABG dyssynchrony and nonviable myocardium (event rate 3% vs. 64%; p < 0.001).
CONCLUSIONS: The presence of severe LV dyssynchrony is associated with poor clinical outcomes despite revascularization. These results advocate a routine assessment of both LV dyssynchrony and viability to predict outcome in systolic heart failure patients undergoing CABG surgery.

Entities:  

Mesh:

Year:  2007        PMID: 17903629     DOI: 10.1016/j.jacc.2007.03.070

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  15 in total

1.  Predicting cardiac events using ventricular dyssynchrony in patients who received implantable cardioverter defibrillators: Are more treatment options required?

Authors:  Keiichiro Yoshinaga
Journal:  J Nucl Cardiol       Date:  2015-11-24       Impact factor: 5.952

2.  Predictors of long-term mortality with cardiac resynchronization therapy in mild heart failure patients with left bundle branch block.

Authors:  Yitschak Biton; Jason Costa; Wojciech Zareba; Jayson R Baman; Ilan Goldenberg; Scott McNitt; Scott D Solomon; Bronislava Polonsky; Valentina Kutyifa
Journal:  Clin Cardiol       Date:  2018-10       Impact factor: 2.882

3.  Left ventricular dyssynchrony assessment by phase analysis from gated PET-FDG scans.

Authors:  Aju P Pazhenkottil; Ronny R Buechel; Rene Nkoulou; Jelena-Rima Ghadri; Bernhard A Herzog; Lars Husmann; Mathias Wolfrum; Silke M Küest; Michael Fiechter; Oliver Gaemperli; Philipp A Kaufmann
Journal:  J Nucl Cardiol       Date:  2011-06-14       Impact factor: 5.952

4.  Neuronal damage and abnormal contraction: Is the circle of synchronicity complete?

Authors:  Claudio Marcassa
Journal:  J Nucl Cardiol       Date:  2018-01-11       Impact factor: 5.952

Review 5.  Clinical Assessment and Implication of Left Ventricular Mechanical Dyssynchrony in Patients with Heart Failure.

Authors:  Yi-Hsin Chan; Chun-Li Wang; Chi-Tai Kuo; Yung-Hsin Yeh; Chia-Tung Wu; Lung-Sheng Wu
Journal:  Acta Cardiol Sin       Date:  2013-11       Impact factor: 2.672

Review 6.  Nuclear cardiology and heart failure.

Authors:  Raffaele Giubbini; Elisa Milan; Francesco Bertagna; Fernando Mut; Marco Metra; Carlo Rodella; Maurizio Dondi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12       Impact factor: 9.236

7.  Yield of left ventricular dyssynchrony by gated SPECT MPI in patients with heart failure prior to implantable cardioverter-defibrillator or cardiac resynchronization therapy with a defibrillator: Characteristics and prediction of cardiac outcome.

Authors:  Nili Zafrir; Tamir Bental; Boris Strasberg; Alejandro Solodky; Israel Mats; Ariel Gutstein; Ran Kornowski
Journal:  J Nucl Cardiol       Date:  2015-11-12       Impact factor: 5.952

8.  Prognostic Value of Phase Analysis for Predicting Adverse Cardiac Events Beyond Conventional Single-Photon Emission Computed Tomography Variables: Results From the REFINE SPECT Registry.

Authors:  Keiichiro Kuronuma; Robert J H Miller; Yuka Otaki; Serge D Van Kriekinge; Marcio A Diniz; Tali Sharir; Lien-Hsin Hu; Heidi Gransar; Joanna X Liang; Tejas Parekh; Paul B Kavanagh; Andrew J Einstein; Mathews B Fish; Terrence D Ruddy; Philipp A Kaufmann; Albert J Sinusas; Edward J Miller; Timothy M Bateman; Sharmila Dorbala; Marcelo Di Carli; Balaji K Tamarappoo; Damini Dey; Daniel S Berman; Piotr J Slomka
Journal:  Circ Cardiovasc Imaging       Date:  2021-07-20       Impact factor: 7.792

9.  Assessment of distribution and evolution of mechanical dyssynchrony in a porcine model of myocardial infarction by cardiovascular magnetic resonance.

Authors:  Khaled Z Abd-Elmoniem; Miguel Santaularia Tomas; Tetsuo Sasano; Sahar Soleimanifard; Evert-Jan P Vonken; Amr Youssef; Harsh Agarwal; Veronica L Dimaano; Hugh Calkins; Matthias Stuber; Jerry L Prince; Theodore P Abraham; M Roselle Abraham
Journal:  J Cardiovasc Magn Reson       Date:  2012-01-06       Impact factor: 5.364

10.  Clinical implication of mechanical dyssynchrony in heart failure.

Authors:  Qing Zhang; Cheuk-Man Yu
Journal:  J Cardiovasc Ultrasound       Date:  2012-09-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.